UK-based AstraZeneca has signed an agreement with US-based Foundation Medicine to develop a new diagnostic assay for Lynparza (olaparib).

Lynparza is an orally administered poly ADP-ribose polymerase (PARP) inhibitor that leverages on tumour DNA repair pathway deficiencies to eliminate cancer cells.

Under the deal, Foundation Medicine will develop a regulatory approved product based on its quality systems regulations (QSR) compliant version of FoundationOne comprehensive genomic profiling platform.

"This agreement supports the broad development programme for our first-in-class PARP inhibitor, Lynparza."

A multiple class of genomic alterations across a range of genes involved in homologous recombination repair (HRR) will be detected by the new assay, which is based on a scientifically selected panel of genes involved in driving the HRR process.

AstraZeneca Lynparza global medicine lead Nina Mojas said: "This agreement supports the broad development programme for our first-in-class PARP inhibitor, Lynparza.

"Utilising Foundation Medicine’s leading capabilities in molecular information will help our work to assess the potential of the medicine to address unmet patient need across a number of cancers driven by DNA repair deficiencies, including and significantly beyond the BRCA mutations."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The assay will be developed in conjunction with the clinical programme for Lynparza, as a part of a coordinated drug-diagnostic regulatory strategy.

The companion diagnostic assay will assist physicians to determine the specific patients who will be benefitted from AstraZeneca’s PARP inhibitor, Lynparza.